Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response

566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis

(2015) Walter Reinisch et al.   GASTROENTEROLOGY

563 Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated With Infliximab Maintenance Therapy

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Su2079 Certolizumab Pegol Plasma Concentration and Clinical Remission in Crohn's Disease

(2015) William J. Sandborn et al.   GASTROENTEROLOGY

Sa2045 Relationship Between Drug Serum Concentration and Clinical Activity in Patients With Crohn Disease Who Achieved Remission With Adalimumab - a Prospective Study

(2015) Giorgia Bodini et al.   GASTROENTEROLOGY

P253 Transient versus sustained antibodies to infliximab: Possibility to overcome low titer antibody responses by dose optimisation

(2012) N. Van de Casteele et al.   Journal of Crohns & Colitis

Do Not Assume Symptoms Indicate Failure of Anti–Tumor Necrosis Factor Therapy in Crohn's Disease

(2011) David H. Bruining et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

(2010) Gary R. Lichtenstein et al.   Clinical Gastroenterology and Hepatology

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

(2009) G. R. LICHTENSTEIN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

(2009) Andrea Cassinotti et al.   INFLAMMATORY BOWEL DISEASES

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s disease

(2008) A. C. MOSS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

(2008) R. L. WEST et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY